Research & Development

R&D Overview Our R&D Approach Pipeline Technology Platforms Manufacturing

Other Information

Clinical Trials Expanded Access Investigator Sponsored Studies

Pipeline

Pipeline of Key Proprietary Products

We have a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer.

Development Candidates

Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Review
ALKS 3831
Schizophrenia / Bipolar I Disorder*
ALKS 4230
Immuno-oncology (Intravenous Dosing)
Immuno-oncology (Subcutaneous Dosing)
Selective HDAC Inhibitors
Neurodegenerative Disorders (Orphan)
Neurodegenerative Disorders (Prevalent, Non-orphan)
Oncology
*PDUFA target action date Nov. 15, 2020
Oncology CNS